Congress Park Capital LLC Boosts Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Congress Park Capital LLC increased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 24.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,455,495 shares of the biotechnology company’s stock after acquiring an additional 477,417 shares during the period. Heron Therapeutics comprises approximately 1.4% of Congress Park Capital LLC’s holdings, making the stock its 23rd largest position. Congress Park Capital LLC’s holdings in Heron Therapeutics were worth $3,757,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HRTX. The Manufacturers Life Insurance Company raised its stake in shares of Heron Therapeutics by 16.0% in the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 6,328 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Heron Therapeutics by 21.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock worth $90,000 after buying an additional 7,927 shares in the last quarter. King Wealth Management Group raised its position in Heron Therapeutics by 52.3% in the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock worth $46,000 after buying an additional 8,000 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in Heron Therapeutics by 49.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 10,578 shares during the period. Finally, Zacks Investment Management boosted its holdings in shares of Heron Therapeutics by 2.4% during the 3rd quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company’s stock valued at $946,000 after acquiring an additional 11,320 shares during the last quarter. 80.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Stock Up 3.3 %

Heron Therapeutics stock opened at $1.57 on Friday. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The company has a market cap of $238.80 million, a P/E ratio of -8.72 and a beta of 1.60. The business has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $1.97.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter last year, the firm posted ($0.17) earnings per share. Research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.